Ref I3
Computational Service
Confidence Reported
Scoped After Feasibility Review
Service Overview
Bispecific design is a geometry and assembly problem as much as a binding problem. Two paratopes must engage two epitopes simultaneously with a spatial arrangement that supports the intended mechanism, the chains must pair correctly during expression, and the resulting molecule must remain stable and manufacturable. We model the format options, predict chain mispairing risk, optimise linkers and hinge geometry, and simulate the ternary arrangement where cell-to-cell bridging is the mechanism.
Key Features & Advantages
Format Selected For Mechanism
CrossMab, knob-into-hole, DuoBody-style, scFv fusion, DVD-Ig and tandem formats are compared against your required geometry, valency and effector profile instead of assumed.
Mispairing Risk Quantified
Chain pairing is modelled explicitly and the interface engineering needed to enforce correct assembly is designed, since mispairing is the dominant manufacturing problem for bispecifics.
Geometry Modelled For Bridging
Where the mechanism depends on bridging two cells or two receptors, the span, flexibility and reach of the construct are simulated rather than inferred from a cartoon.
Developability Assessed Per Format
Aggregation, thermal stability and purification behaviour are assessed for each candidate format, so the chosen design can survive the process it will face.
Where This Service Is Used
1Designing T-cell engagers that bridge a tumour antigen and a T-cell receptor complex
2Building dual-targeting antibodies for improved selectivity or avidity
3Creating biparatopic molecules binding two epitopes on the same antigen
4Converting two validated binders into a single bispecific construct
5Troubleshooting an existing bispecific that expresses poorly or mispairs
Methods and Techniques Applied
1Format evaluation against mechanism, valency, geometry and effector requirements
2Structural modelling of each chain, of the assembled construct and of the antigen complexes
3Chain pairing analysis and design of interface mutations to enforce correct assembly
4Linker and hinge design with conformational sampling to establish reach and flexibility
5Ternary arrangement modelling and simulation for bridging mechanisms such as immune cell engagement
6Developability and stability assessment across the candidate formats
What We Need From You
1Sequences of both binding arms, with any structural or epitope information available
2The intended mechanism, including whether simultaneous engagement is required
3Valency, geometry, effector function and half-life requirements
4Manufacturing constraints: expression system, purification approach, format preferences
What You Receive
1Format recommendation with a comparison of the options against your requirements
2Complete designed sequences including linkers and interface mutations
3Structural models of the assembled construct and of the antigen complexes
4Chain pairing risk assessment with the engineering solution applied
5Developability assessment and a prioritised construction and testing plan
What We Compute and Report
1Assembled construct models with both antigen complexes
2Chain pairing energetics quantifying the mispairing risk of each design
3Span and reach distributions from linker conformational sampling
4Aggregation and thermal stability risk indicators per candidate format
5Geometric feasibility assessment for simultaneous engagement of both targets
Questions We Are Asked Before Scoping
Which format should we choose?
▸It depends on mechanism, valency, required geometry and your manufacturing platform. We compare candidates against your constraints and recommend, with the trade-offs stated rather than hidden.
Can you predict whether the bispecific will work functionally?
▸We can predict geometric feasibility, assembly behaviour and stability risk. Functional potency depends on cell biology, receptor density and signalling thresholds, which require cell-based testing.
How do you reduce mispairing?
▸Through interface engineering such as knob-into-hole style designs, charge pairing and domain crossover, selected and modelled for your specific sequences rather than applied generically.
Interpretation and Limitations
Computational predictions prioritise hypotheses; they do not independently establish binding, biological activity, therapeutic efficacy, safety or clinical validity. Performance depends on input quality, target class, the structural evidence available and the applicability domain of the selected methods. Scores used for ranking are comparative devices and should not be read as measured quantities. All deliverables are for research use only and are not intended for diagnostic or therapeutic use.
Is This the Right Service for You?
Choose this when
Two validated binders must be combined and the architecture is not yet fixed
The mechanism depends on engaging two targets simultaneously
An existing bispecific expresses poorly or mispairs and the cause is unclear
Consider another service when
Only one target is involved
Full-Length IgG Antibody Design A payload rather than a second binding arm is being added
ADC Linker-Payload Design What Goes Wrong, and How We Handle It
These are the failure modes that produce confident-looking results which do not survive the next experiment. Each one is designed against rather than discovered afterwards.
Format chosen before the mechanism is defined
Required geometry, valency and effector profile are fixed first; that alone eliminates most of the hundred published architectures.
Chain mispairing discovered during production
Pairing is modelled and interface engineering is designed in, with the residual risk ranked between candidate designs.
Two arms that bind well but cannot reach both targets together
Span, linker flexibility and both antigen complexes are modelled as one system before construction.
A Worked Example
A T-cell engager that bound both targets but killed nothing
The situation
Both arms showed good affinity in isolation while the cell-killing assay was negative.
What the work involved
The assembled construct was modelled with both antigen complexes, and linker conformational sampling was used to compute the accessible span between the two binding sites.
What came back
The geometry could not bridge the two membranes at the epitope positions involved. Redesign moved one arm to a membrane-proximal epitope and lengthened the linker, with three alternatives modelled for testing.
Illustrative of the shape this work takes. Details are generalised, no client or target is identified, and scope and outcome vary with the system in question.
What Published Work Reports
The results below were published by independent groups and are cited to show what these computational approaches have achieved in the literature. They are not ICDMO project results, and outcomes vary substantially between targets, datasets and programmes. We do not promise comparable results for any particular project.
10- to 140-fold affinity improvements from computational design
Computational interface redesign produced a tenfold affinity improvement in cetuximab, reaching 52 pM, and a 140-fold improvement to 30 pM for an anti-lysozyme model antibody — improvements achieved by designing a small number of interface substitutions rather than by library selection.
Lippow, Wittrup & Tidor, Nature Biotechnology, 2007 ↗Interface models predict which substitutions help, with measurable accuracy
A 2024 study combining structural interface analysis with sequence-derived evolutionary information reported a predictive model for antibody–antigen interaction with an area under the curve of 0.83 and precision of 0.89 on held-out data, and experimentally confirmed a designed point mutation that improved affinity 2.5-fold to 2 nM. Typical computational maturation gains are modest per mutation, which is why a designed panel is measured rather than a single variant.
Experimental validation study, 2024 ↗Service Workflow
1
Scientific Consultation
We discuss the objective, the decision it supports and the data you hold. Nothing is quoted before we understand what the result has to answer.
2
Feasibility Review
We check that the data, target class and available structural evidence can support the proposed approach, and say plainly where they cannot.
3
Technical Proposal
Scope, methods, deliverables, timeline and price are confirmed in writing, together with the limitations we expect to report.
4
Computation and QC
The analysis runs on pinned tool versions in a containerised environment, with quality checkpoints and method comparison where that is informative.
5
Report and Follow-Up
You receive the ranked results, the documented methods, the limitations and a proposed validation plan, plus support in interpreting them.
Service Process
1
Online Consultation
›
2
Solution Matching
›
3
Service Contract
›
4
Project Execution
›
5
Data Delivery
Specifications & Turnaround
Note: ICDMO delivers computational (in silico) services. Results prioritise hypotheses for testing; they do not by themselves establish binding, biological activity, efficacy or safety. All deliverables are for research use only and are not intended for diagnostic or therapeutic use. Downstream experimental work is scoped separately and executed through qualified partners.
Get a Custom Quote
Our scientific team responds within 24 hours with a detailed technical proposal and pricing tailored to your project.
Contact Us Online ConsultationStandard Deliverables
✓Sequence-verified final product
✓Full QC documentation
✓Certificate of Analysis (CoA)
✓Electronic data files
✓Project completion report
Why ICDMO?
Computational CDMO Focus
Reproducible, Versioned Pipelines
Confidence & Limitations Reported
Experiment-Aware Recommendations
Response Within One Business Day